Ameri Holdings

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

NAPLES, Fla. , May 3, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of Enveric common stock held of record as of 5:00 p.m.

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

NAPLES, Fla. , April 6, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate in three upcoming investor conferences: Benzinga Psychedelics Capital Conference  Date: Tuesday, April 19th at 11:10 a.m.

Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022

NAPLES, Fla. , March 31, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today reported its financial results for the full year ended December 31, 2021, and provided a business update.

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

NAPLES, Fla., March 29, 2022 /PRNewswire/ -  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces the filing of a provisional patent application based on new discoveries by the Company.

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (WIPO). The Naples, Florida-based neuroscience company developing psychedelic-inspired mental health medicines said additional PCT patent applications are expected to be published over the coming months.

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders              NAPLES, Fla., March 15, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that the Company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (WIPO).

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

NAPLES, Fla. , March 3, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in three upcoming investor conferences: Q1 Virtual Investor Summit Tuesday, March 8 th at 11:45 a.m.

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based derivative molecule, completing the company's broad series of PCT applications covering this family of compounds. The Naples-based biotech company's robust tryptamine-derivative intellectual property portfolio claims novel molecules structurally related to certain naturally occurring psychedelics, such as dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT.

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

NAPLES, Fla., March 1, 2022 /PRNewswire/ --  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines, today announces that it has filed its 10th Patent Cooperation Treaty ("PCT") patent application directed to tryptamine-based derivative molecules, completing the Company's broad series of PCT applications covering this family of compounds.

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences (NASDAQ:ENVB) said it is working with the University of Calgary's Hotchkiss Brain Institute (HBI), a leading neurosciences center of excellence at the Cumming School of Medicine in Calgary, to establish a groundbreaking clinical trial of EVM-101 for the treatment of cancer-related distress (CRD). A clinical trial of EVM-101, a first-generation psychedelic treatment, expected to launch later this year, will be led by HBI researcher, Dr.

Enveric Biosciences collaborates with University of Calgary to establish clinical trial for EVM-101 in cancer related distress

Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy NAPLES, Fla., Feb. 17, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB)("Enveric" or the "Company), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, is working with the University of Calgary's Hotchkiss Brain Institute ("HBI"), a leading neurosciences center of excellence, at the Cumming School of Medicine in Calgary, Canada that is dedicated to advancing brain and mental health research and education, to establish a groundbreaking clinical trial of EVM-101 for the treatment of Cancer Related Distress ("CRD").

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Psychedelics-based company Enveric Biosciences (NASDAQ:ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. Transaction Details Enveric granted the underwriter a 45-day option to purchase up to an additional 3 million shares of common stock and/or warrants to purchase up to an additional 3 million shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up to 3 million shares of common stock.

Enveric Biosciences Closes $10 Million Public Offering

Enveric Biosciences (NASDAQ:ENVB) Inc announced the closing of its underwritten public offering that generated gross proceeds of about $10 million.  The company intends to use the net proceeds for working capital and to fund other general corporate purposes.

Enveric Biosciences announces closing of $10M underwritten public offering

NAPLES, Fla. , Feb. 15, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its common stock for gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses.

Enveric Biosciences Announces Closing of $10 Million Public Offering

Enveric Biosciences Inc (NASDAQ: ENVB) has priced its previously announced underwritten public offering of 20 million shares and warrants to purchase up to 20 million shares at a combined price of $0.50 per share. The warrants have an exercise price of $0.55 per share, are exercisable immediately, and will expire five years following the date of issuance.

Enveric Biosciences Shares Fall After $10M Equity Raise

Enveric Biosciences (NASDAQ:ENVB) Inc said it has priced its previously-announced underwritten public offering of 20 million company common shares plus warrants to purchase up to an additional 20 million shares of its common stock, for expected gross proceeds of $10 million.   Enveric noted that each common share is being sold at a price of $0.50, with each warrant enabling the holder to purchase an additional share of the company at a price of $0.55.

Enveric Biosciences prices its $10 million public offering

NAPLES, Fla. , Feb. 11, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the pricing of its previously announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its common stock.

Enveric Biosciences Announces Pricing of $10 Million Public Offering

Enveric Biosciences (NASDAQ:ENVB) said that two new molecules, EV104a and EV104b, have been created to treat osteoarthritis (OA) along with other pain conditions and that pre-clinical in vitro testing is now underway. The biotech recently licensed a platform technology from Diverse Biotech that has led to the successful synthesis of the two new chemical entity conjugates of cannabidiol (CBD) linked to nonsteroidal anti-inflammatory drug (NSAID) celecoxib.

Enveric Biosciences advancing clinical plans as it announces two new molecules to treat osteoarthritis and other pain conditions

Psychedelics-based neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis and other pain indications. EV104a and EV104b are specifically designed to optimize pharmacokinetics and therapeutic synergy via improved delivery, targeting abilities, and potency to potentially be more efficacious and display fewer side effects than current treatments.

Enveric Biosciences Files Provisional Patent For CBD+Celecoxib Conjugate For Osteoarthritis

Target Indications include Osteoarthritis and Other Pain Conditions NAPLES, Fla. , Feb. 8, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health, and oncology treatments, today announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis ("OA") and other pain indications.

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate

NAPLES, Fla. , Jan. 27, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences: Citi's Psychedelic Drug Call Series Tuesday, February 8 th at 10:00 a.m.

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

Enveric Biosciences (NASDAQ:ENVB) issued a letter to shareholders from its CEO Joseph Tucker, highlighting the milestones of 2021 and the strategic plans for 2022. “2021 was a foundational year that set the stage for our company by assembling a talented and expert team to execute our strategy for the future,” said Tucker in a statement.

Enveric Biosciences CEO says company to focus on drug development, drug discovery, intellectual property strategy in 2022

NAPLES, Fla. , Jan. 18, 2022 /PRNewswire/ -   Enveric Biosciences   (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to shareholders from Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences.

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

NAPLES, Fla., Jan. 6, 2022 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C.

Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Enveric Biosciences (NASDAQ:ENVB) announced that Bob Dagher will be joining the company as its chief medical officer. The psychedelic company said that Dagher brings over 20 years of experience working in clinical development in the pharmaceutical industry for both small and large pharmaceutical companies and as a board-certified physician from the American Board of neurology and psychiatry.

News for Ameri Holdings Stock (ENVB)